5-(trifluoromethoxy)indan-1-ol | 1400702-22-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-(trifluoromethoxy)indan-1-ol
• 英文别名: 5-(trifluoromethoxy)-2,3-dihydro-1H-inden-1-ol
• CAS: 1400702-22-8
• 化学式: C₁₀H₉F₃O₂
• 分子量: 218.175
• InChiKey: HDBVHUFMISYAOD-UHFFFAOYSA-N

物化性质

• 沸点：
  262.9±40.0 °C(Predicted)
• 密度：
  1.399±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-三氟甲氧基-1-茚酮 、 甲醇 在 dimethyl sulfide borane 、 氯仿 、 氯化铵 、 Brine 、 magnesium sulfate 、 乙醚 、 正己烷 作用下， 以 四氢呋喃 为溶剂， 反应 18.33h， 以to give a crude 5-(trifluoromethoxy)indan-1-ol (62.5 mg)的产率得到5-(trifluoromethoxy)indan-1-ol
  参考文献：
  名称：

  SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY

  摘要：

  提供具有TRPM8拮抗活性的磺胺类化合物。提供式(I)的磺胺类化合物或其药学上可接受的盐或前药，其中，环A是由(a)吡啶与苯环缩合；或(b)吡啶与单环芳杂环缩合构成的双环芳香杂环，环A与构成环A的吡啶环上的氮原子相邻的碳原子上的磺酰氨基团结合，环B为(a)单环或双环芳香烃；(b)单环或双环脂环烃；(c)单环或双环芳杂环；或(d)单环或双环非芳杂环，环C为(a)苯环；或(b)单环芳杂环，其他符号与规范中定义的相同。

  公开号：

  US20140005393A1

文献信息

• [EN] SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY<br/>[FR] COMPOSÉS SULFONAMIDES AYANT UNE ACTIVITÉ D'ANTAGONISTE DE TRPM8
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2012124825A1

  公开（公告）日：2012-09-20

  Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

  提供具有TRPM8拮抗活性的磺胺类化合物。公式（I）的磺胺类化合物或其药学上可接受的盐，或其前药：（I）其中环A是由（a）吡啶与苯环融合；或（b）吡啶与单环芳香杂环融合而成的双环芳香杂环，环A与构成环A的吡啶环上的氮原子相邻的碳原子上的磺酰氨基团结合，环B是（a）单环或双环芳香烃；（b）单环或双环脂环烃；（c）单环或双环芳香杂环；或（d）单环或双环非芳香杂环，环C是（a）苯环；或（b）单环芳香杂环，其他符号与规范中定义的相同。
• [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：BIOMARIN PHARM INC

  公开号：WO2020257487A1

  公开（公告）日：2020-12-24

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法，例如与甘氧酸氧化酶（GO）或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱，例如原发性高草酸尿症。
• Sulfonamide compounds having TRPM8 antagonistic activity
  申请人：Tsuzuki Yasuyuki

  公开号：US08987445B2

  公开（公告）日：2015-03-24

  Sulfonamide compounds having TRPM8 antagonistic activity are provided. A sulfonamide compound of formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) wherein Ring A is bicyclic aromatic heterocycle comprised of (a) pyridine is condensed with benzene; or (b) pyridine is condensed with monocyclic aromatic heterocycle, and Ring A binds to a sulfonylamino moiety on a carbon atom adjacent to a nitrogen atom of the pyridine ring constituting Ring A, Ring B is (a) monocyclic or bicyclic aromatic hydrocarbon; (b) monocyclic or bicyclic alicyclic hydrocarbon; (c) monocyclic or bicyclic aromatic heterocycle; or (d) monocyclic or bicyclic non-aromatic heterocycle, Ring C is (a) benzene; or (b) monocyclic aromatic heterocycle, and other symbols are the same as defined in the specification.

  提供具有TRPM8拮抗活性的磺胺类化合物。提供式(I)的磺胺类化合物或其药学上可接受的盐或前药：其中环A是由(a)吡啶和苯缩合形成的双环芳香杂环；或(b)吡啶和单环芳香杂环缩合形成的双环芳香杂环，环A与构成环A的吡啶环上的氮原子相邻的碳原子上的磺酰氨基团结合，环B是(a)单环或双环芳香碳氢化合物；(b)单环或双环脂环碳氢化合物；(c)单环或双环芳香杂环；或(d)单环或双环非芳香杂环，环C是(a)苯；或(b)单环芳香杂环，其他符号与说明书中定义的相同。
• Glycolate oxidase inhibitors for the treatment of disease
  申请人：BIOMARIN PHARMACEUTICAL INC.

  公开号：US11384055B2

  公开（公告）日：2022-07-12

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述的是化合物、制造此类化合物的方法、含有此类化合物的药物组合物和药剂，以及使用此类化合物治疗或预防与乙醛酸氧化酶（GO）相关的疾病或紊乱的方法。此类疾病或紊乱包括，例如，与产生过量草酸盐有关的乙醛酸代谢紊乱，包括原发性高草酸尿症。
• GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
  申请人：BIOMARIN PHARMACEUTICAL INC.

  公开号：US20210171474A1

  公开（公告）日：2021-06-10

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.